Abstract
Objective: To assess the real-world use, clinical outcomes, and adherence to novel P2Y12 inhibitors. Methods: We evaluated 1,093 consecutive acute myocardial infarction patients undergoing a percutaneous intervention. Patients were derived from a prospective, multicenter, nationwide registry and were followed for 30 days; 381 patients (35%) received clopidogrel, 468 (43%) received prasugrel, and 244 (22%) received ticagrelor. Patients treated with clopidogrel were older and more likely to suffer from chronic renal failure and stroke and/or present with non-ST-elevation myocardial infarction (NSTEMI) (p < 0.01 for all). Independent predictors of undertreatment with novel P2Y12 inhibitors included: older age (OR 0.17; 95% CI 0.1-0.27, p < 0.0001), a prior stroke (OR 0.41; 95% CI 0.2-0.68, p = 0.008), and NSTEMI (OR 0.37; 95% CI 0.26-0.54, p < 0.0001). Results: Novel P2Y12 inhibitors were associated with a lower incidence of cardiovascular events, major bleeding, and/or death (7.6 vs.11%, HR 0.67; 95% CI 0.43-1, p = 0.05). However, after a multivariate analysis this trend was not statistically significant. Patients discharged with ticagrelor versus thienopyridines demonstrated a higher rate of crossover to other P2Y12 inhibitors (11 vs. 5%, p = 0.03). Conclusions: In a real-world cohort, there was an underutilization of novel P2Y12 inhibitors which was more pronounced in higher-risk subsets that might benefit from novel P2Y12 inhibitors at least as much as other patients.
Journal Section:
Editor's choice
References
1.
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK: Clopidogrel in unstable angina to prevent recurrent events trial investigators: effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
[PubMed]
2.
Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, et al: 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;64:e139-e228.
[PubMed]
3.
O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, et al: 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e362-e425.
[PubMed]
4.
Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, et al: ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the Management of Acute Coronary Syndromes (ACS) in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
[PubMed]
5.
Steg PG, James SK, Atar D, Badano LP, Lundqvist CB, Borger MA, Mario CD, Dickstein K, Ducrocq G, Fernandez-Aviles F, et al: ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC). Eur Heart J 2012;33:2569-2619.
[PubMed]
6.
Windecker S, Kolh P, Alfonso F, Collet J-P, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, et al: 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541-2619.
[PubMed]
7.
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al; PLATO Investigators: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
[PubMed]
8.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann F-J, Ardissino D, De Servi S, Murphy SA, et al; TRITON-TIMI 38 Investigators: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
[PubMed]
9.
Bae JP, Faries DE, Ernst FR, Lipkin C, Zhao Z, Moretz C, Lieu HD, Effron MB: Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States. Curr Med Res Opin 2014;30:2207-2216.
[PubMed]
10.
Bueno H, Sinnaeve P, Annemans L, Danchin N, Licour M, Medina J, Pocock S, Sánchez-Covisa J, Storey RF, Jukema JW, et al; EPICOR Investigators: Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: insights from EPICOR, an international study of current practice patterns. Eur Heart J Acute Cardiovasc Care 2016;5:3-12.
[PubMed]
11.
Damman P, Varenhorst C, Koul S, Eriksson P, Erlinge D, Lagerqvist B, James SK: Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel [from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)]. Am J Cardiol 2014;113:64-69.
[PubMed]
12.
Sherwood MW, Wiviott SD, Peng SA, Roe MT, Delemos J, Peterson ED, Wang TY: Early clopidogrel versis prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the national cardiovascular data registry. J Am Heart Assoc 2014;3:e000849.
[PubMed]
13.
Alexopoulos A, Goudevenos JA, Xanthopoulou X, Deffereos S, Sitafidis G, Kanakakis I, Hamilos M, Parissis H, Ntalas IV, Angelidis C, et al: Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the Greek Antiplatelet Registry (GRAPE). Int J Cardiol 2013;168:5329-5335.
[PubMed]
14.
Sandhu A, Seth M, Dixon S, Share D, Wohns D, Lalonde T, Moscucci M, Riba AL, Grossman M, Gurm HS: Contemporary use of prasugrel in clinical practice: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Circ Cardiovasc Qual Outcomes 2013;6:293-298.
[PubMed]
15.
Karve AM, Seth M, Sharma M, LaLonde T, Dixon S, Wohns D, Gurm HS: Contemporary use of ticagrelor in interventional practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium). Am J Cardiol 2015;115:1502-1506.
[PubMed]
16.
Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, et al; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction: Universal definition of myocardial infarction. Circulation 2007;116:2634-2653.
[PubMed]
17.
James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, et al: Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2010;122:1056-1067.
[PubMed]
18.
James SK, Storey RF, Khurmi NS, Husted S, Keltai M, Mahaffey KW, Maya J, Morais J, Lopes RD, Nicolau JC, et al; PLATO study group: Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation 2012;125:2914-2921.
[PubMed]
19.
Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, Cannon CP, Heras M, Lopes RD, Morais J, et al; PLATO study group: Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes 2012;5:680-688.
[PubMed]
20.
Stark U, Brodmann M, Lueger A, Stark G: Antiarrhythmic effects of adenosine on ischemia-induced ventricular fibrillation. J Crit Care 2001;16:8-16.
[PubMed]
21.
Stutzmann GE, Marek GJ, Aghajanian GK: Adenosine preferentially suppresses serotonin2A receptor-enhanced excitatory postsynaptic currents in layer V neurons of the rat medial prefrontal cortex. Neuroscience 2001;105:55-69.
[PubMed]
© 2016 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2016
You do not currently have access to this content.
